检索结果-南通市图书馆

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated,EGFR-mutated,advanced non-small cell lung cancer:data froma randomized phase III trial(AENEAS)

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2024年第9期44卷 1005-1017页

作者： Shun lu Xiaorong Dong Hong Jian jianhua chen Gongyan chen Yuping Sun Yinghua Ji ZipingWang jianhua Shi Junguo lu Shaoshui chen Dongqing Lv Guojun Zhang Chunling Liu Juan Li Xinmin Yu Zhong Lin Zhuang Yu ZhehaiWang Jiuwei Cui Xingxiang Xu Jian Fang Jifeng Feng Zhi Xu RuiMa Jie Hu Nong Yang Xiangdong Zhou XiaohongWu chengping Hu Zhihong Zhang You lu Yanping Hu Liyan Jiang Qiming wang Renhua Guo Jianying Zhou Baolan Li Chunhong Hu Wancheng Tong Helong Zhang LinMa Yuan chen zhijun Jie Yu Yao Longzhen Zhang JieWeng Weidong Li Jianping Xiong Xianwei Ye Jianchun Duan Haihua Yang Meili Sun HongyingWei JiaweiWei Zheyu Zhang QiongWu Department of Medical Oncology Shanghai Chest Hospital Shanghai JiaoTong UniversityShanghaiP.R.China Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and TechnologyWuhanHubeiP.R.China Department of Medical Oncology-Chest Hunan Cancer Hospital&The Affiliated Cancer Hospital of Central South University Xiangya School of MedicineChangshaHunanP.R.China Thoracic OncologyMedicine HarbinMedical University Cancer HospitalHarbinHeilongjiangP.R.China Department of Oncology Jinan Central HospitalJinanShandongP.R.China Department of Oncology First Affiliated Hospital of Xinxiang Medical UniversityXinxiangHenanP.R.China Department of Chest Medicine Beijing Cancer HospitalBeijingP.R.China Department of Internal Medicine Linyi Cancer HospitalLinyiShandongP.R.China Department of Respiratory Medicine Nantong Tumor HospitalNantongJiangsuP.R.China Department of Oncology Binzhou Medical University HospitalBinzhouShandongP.R.China Breath Internal Medicine Taizhou Hospital of Zhejiang ProvinceLinhaiZhejiangP.R.China Department of Respiration The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China Department of lung Internal Medicine Affiliated Tumor Hospital of Xinjiang Medical UniversityUrumqiXinjiangP.R.China Department of Thoracic Oncology Sichuan Cancer HospitalChengduSichuanP.R.China Thoracic Medical Oncology Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)HangzhouZhejiangP.R.China Department of Thoracic Oncology The Fifth Subsidiary Sun Yat-sen University HospitalZhuhaiGuangdongP.R.China Department of Oncology The Affiliated Hospital of QingdaoUniversityQingdaoShandongP.R.China Department of Oncology Shandong Cancer HospitalJinanShandongP.R.China Department of Oncology The First BethuneHospital of Jilin UniversityChangchunJilinP.R.China Department of Respiration Northern Jiangsu People’s Hospital Affiliated to Yangzhou UniversityYangzhouJiangsuP.R.China Department of Internal

Background:The initial randomized,double-blinded,actively controlled,phase III ANEAS study(NCT03849768)demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first-line therapy in epidermal growth factor receptor(EGFR)-mutated advanced non-small cell lung cancer(NSCLC).Metastatic disease in the central nervous system(CNS)remains a challenge in the management of *** study aimed to compare the efficacy of aumolertinib versus gefitinib among patients with baseline CNS metastases in the ANEAS ***:Eligible patients were enrolled and randomly assigned in a 1:1 ratio to orally receive either aumolertinib or gefitinib in a double-blinded *** with asymptomatic,stable CNS metastases were ***-up imaging of the same modality as the initial CNS imaging was performed every 6 weeks for 15 months,then every *** responsewas assessed by a neuroradiological blinded,independent central review(neuroradiological-BICR).The primary endpoint for this subgroup analysis was CNS progression-free survival(PFS).Results:Of the 42. patients enrolled and randomized in the ANEAS study,106 patients were found to have CNS metastases(CNS Full Analysis Set,cFAS)at baseline by neuroradiological-BICR,and 60 of them had CNS target lesions(CNS Evaluable for Response,cEFR).Treatment with aumolertinib significantly prolonged median CNS PFS compared with gefitinib in both cFAS(2..0 vs.8.3 months;hazard ratio[HR]=0.31;95%confidence interval[CI],0.17-0.56;P2..0 vs.8.3 months;HR=0.2.;95%CI,0.11-0.57;P<0.001).The confirmed CNS overall response rate in cEFRwas 85.7%and 75.0%in patients treated with aumolertinib and gefitinib,*** risk analysis showed that the estimated probability of CNS progression without prior non-CNS progression or death was consistently lower with aumolertinib than with gefitinib in patients with and without CNSmetastases at *** new safety findings were ***:The

关键词： aumolertinib brain metastasis non-small cell lung cancer third-generation EGFR-TKI

A High Data-Rate Software Defined Radio Receiver Suited for FPGA Platforms

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A High Data-Rate Software Defined Radio Receiver Suited for ...

医疗机构落实药品集中带量采购政策中的问题及建议

The First International Workshop on Software Radio Technology

作者： zhijun chen,{2. Zhan and jianhua lu Department of Electronic Engineering,Tsinghua University,Beijing,China

Although Alternate Parallel Receiver(APRX)could effectively improve the maximum demodulating rate of the receiver,its frequency domain processing module consumes a large amount of multiplication units when the number of parallel input channels is large,making it unsuitable for use on FPGA software defined radio *** paper proposes an optimization scheme by introducing partitioned convolution and exploring the spectrum characteristic of the APRX input data,reducing the usage of multipliers greatly with no throughput *** the optimization,the number of real multipliers used in the frequency-domain processing module of the 16-ary APRX is reduced from about 576 to 68,with little performance *** optimized APRX is fairly suitable for FPGA software defined radio platform applications.

关键词： FPGA APRX optimization partitioned convolution

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

中华医院管理杂志 2024年第7期40卷 535-540页

作者：孔维华谯琦刘国强陈楠沈承武陈琦邱峰王建华姜玲卢庆红伍俊妍王亚峰林丽开冯佳佳程虹武汉大学医院管理研究所武汉430071 武汉大学中南医院药学部武汉430071 河北医科大学附属第三医院药学部石家庄050051 郑州人民医院药学部郑州450003 山东第一医科大学附属省立医院药学部济南250021 贵州省人民医院药学部贵阳550002 重庆医科大学附属第一医院药学部重庆400016 新疆医科大学附属第一医院药学部乌鲁木齐830011 安徽省立医院药学部合肥230001 江西省儿童医院药学部南昌360000 中山大学孙逸仙纪念医院药学部广州510120 青海省人民医院药学部西宁810000

目的探讨医疗机构实施药品集中带量采购(以下简称集采)政策过程中面临的问题,并提出相应的优化建议。方法基于德尔菲法,于2.2.年8—12.,通过立意抽样选取全国11名三级甲等医院药学专家进行调查研究,调查内容为"推进国家药品集采提速扩... 详细信息

目的探讨医疗机构实施药品集中带量采购(以下简称集采)政策过程中面临的问题,并提出相应的优化建议。方法基于德尔菲法,于2.2.年8—12.,通过立意抽样选取全国11名三级甲等医院药学专家进行调查研究,调查内容为"推进国家药品集采提速扩面、集采医保资金结余留用的相关政策建议"。结果调查参与者反馈了医疗机构在药品集采政策实施中存在的系列问题,并提出了相应的优化方法。专家咨询的肯德尔和谐系数为0.332.P<0.05),表明专家意见具有较好的一致性和集中性。其中,关于药品供应保障问题的赋分最高(重要性均数为4.45分),同时对于加强监测预警和协调调度,切实保障集采药品供应的建议赋分最高且集中程度最高(重要性均数为4.91分,变异系数为0.06)。结论本研究通过德尔菲法调查揭示了医疗机构实施药品集采中的问题并提出优化方法,对于医药领域实施的改进和未来政策调整具有一定的参考价值。

关键词：集体采购药品集中带量采购医保资金结余留用德尔菲法

半导体激光熔覆TiC/H13涂层的抗回火性能

在线全文

学校读者我要写书评

暂无评论

应用激光 2010年第6期30卷 451-455页

作者：鲁燕孔凡志姚建华陈智君楼程华特种装备制造与先进加工技术教育部/浙江省重点实验室(浙江工业大学) 浙江杭州310014 浙江工业大学激光加工技术工程研究中心浙江杭州310014

在热作模具钢H13基体上通过激光熔覆制备出TiC/H13复合涂层,研究不同TiC含量对复合涂层抗回火(600℃)性能的影响。利用扫描电镜、能谱仪和显微硬度计对激光熔覆涂层回火前后的组织、成分、硬度进行了对比分析和测试。TiC质量分数小于2. ... 详细信息

在热作模具钢H13基体上通过激光熔覆制备出TiC/H13复合涂层,研究不同TiC含量对复合涂层抗回火(600℃)性能的影响。利用扫描电镜、能谱仪和显微硬度计对激光熔覆涂层回火前后的组织、成分、硬度进行了对比分析和测试。TiC质量分数小于2. wt.%时,涂层与基体之间保持良好的结合,没有出现明显缺陷,当质量分数为2. wt.%时,颗粒周围出现微裂纹。能谱分析表明复合涂层中的颗粒主要成分是Ti和C。激光熔覆TiC/H13复合涂层回火处理10h和回火前对比,晶粒明显长大,随着TiC含量增加,涂层晶粒越细小,TiC弥散分布于晶界处,抑制枝晶的生长,起到细化晶粒的效果;回火2.h和回火10h的对比发现晶粒长大不明显。硬度测试显示随着TiC质量分数的增加,熔覆层硬度明显增加,回火后仍保持很高的硬度。

关键词：激光熔覆 TiC/H13 复合涂层抗回火

在线全文

学校读者我要写书评

暂无评论

高效液相色谱法测定妇炎灵洗剂中连翘苷含量

中国药业 2018年第4期27卷 23-25页

作者：陈路翟炎妹闫炳雄吴无畏宋志军缪剑华广西壮族自治区药用植物园广西南宁530023 桂林医学院广西桂林541004

目的建立测定妇炎灵洗剂中连翘苷含量的高效液相色谱(HPLC)法。方法色谱柱为Agilent XDB C_18柱(2.0 mm×4.6 mm,5μm),流动相为乙腈-水(2.∶79,V/V),流速为1.0 mL/min,检测波长为2.7 nm。结果连翘苷进样量在0.472.0~4.72. 0μg范围内... 详细信息

目的建立测定妇炎灵洗剂中连翘苷含量的高效液相色谱(HPLC)法。方法色谱柱为Agilent XDB C_18柱(2.0 mm×4.6 mm,5μm),流动相为乙腈-水(2.∶79,V/V),流速为1.0 mL/min,检测波长为2.7 nm。结果连翘苷进样量在0.472.0~4.72. 0μg范围内与峰面积线性关系良好;连翘苷平均回收率为99.47%,RSD为1.67%(n=9)。结论该方法快速,灵敏,操作简便,可作为妇炎灵洗剂含量的控制依据,可供妇炎灵洗剂质量控制标准和相关研究参考。

关键词：妇炎灵洗剂连翘苷高效液相色谱法含量测定